current guidelines and real-world evidence for ros1 testing in nsclc
Published 4 months ago • 10 plays • Length 6:30Download video MP4
Download video MP3
Similar videos
-
21:08
pathologic testing for alk and ros1 aberrations in nsclc | frédérique penault-llorca
-
8:25
egfr & alk/ros1 testing in squamous nsclc
-
6:01
current management of ros1 rearranged nsclc
-
1:24
real world evidence in lung cancer: pros, cons & potential
-
29:51
current & emerging approaches to acquired resistance for alk/ros1
-
50:46
selective, potent, different: next-generation ros1 and trk inhibition in nsclc and other tumors
-
13:55
ros - dr venkata pradeep babu selection of 1st line therapy for ros 1 rearrangement in nsclc
-
31:43
new ideas and new treatment options for acquired resistance for alk/ros1
-
4:49
emerging alk/ros1 tkis for nsclc
-
59:48
patient need for novel therapies in ros1 fusion-positive non-small cell lung cancer
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
3:55
treatment considerations in alk/ros-1–rearranged nsclc
-
2:00:53
ros-1 lung cancer patients (english version)
-
6:30
the role of chemotherapy and immunotherapy in ros1-rearranged nsclc
-
4:55
ros1-rearranged nsclc
-
8:16
trident-1: repotrectinib in ros1-positive nsclc
-
2:40
repotrectinib could be effective for treating ros1 positive nsclc: trident-1 trial
-
3:15
ros1 rearrangements in mnsclc